We represent life sciences innovation companies in every type of strategic and licensing transaction necessary to propel their businesses.
Our life sciences licensing lawyers work with companies from the earliest stages, routinely working with university spin-outs and pre-venture companies. We provide clients with advice and counsel on what we know to be the most critical issues on a startup’s road-map. Our practice advice, technical skill and constant support help prepare clients for eventual partnerships with other pharmaceutical, biotech and medical device companies and venture financings.
Evolution of growth
As life sciences companies mature, they look to negotiate and implement strategic transactions, collaborations and licensing arrangements with other companies, frequently the largest pharma, biotech and device companies in the world. We routinely negotiate with those companies and their subsidiaries and we know the structures and strategies that produce win-win deals.
Our clients don’t just look to us for our licensing and partnering experience. Gunderson Dettmer clients are at the forefront of the innovation economy and our firm supports these companies in every type of transaction, from early-stage financings to multi-billion dollar exits. We also pioneered many of the compensation practices that have become standard for venture-backed companies to make sure our clients have the best team to propel their growth. Our tax lawyers are adept are figuring out the best balance between tax advantages and business purposes even in cross-border deals.
- VC Law Firm of the Year by LMG for 2022
- Finance/Transactional Impact Deal of the Year for the $1.6B acquisition of client ARMO Biosciences by Eli Lilly
- 4 of our partners are recognized as “Transactional Stars”
“Gunderson’s team was a true partner for True North—an extension of our management. We needed every bit of their experience with complex transactions to make this happen in a way that benefitted everyone. Their strategic guidance, knowledge of our investors and their needs, and ability to structure financings and exit transactions in creative, win-win ways, really guided us toward success from the very beginning."
Handled 600+ licensing and other strategic transactions for life sciences companies since 2015
Represented life sciences clients in 500+ financings raising $14B+ since 2017